Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.52 |
| ▸ | GBA1 | P04062 | 7/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079149 | 0.98 | HRH4 (0.57) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL18489327 | 0.98 | HRH4 (0.57) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL3536093 | 0.95 | HRH4 (0.55) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL12265820 | 0.95 | HRH4 (0.55) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL9926315 | 0.95 | HRH4 (0.51) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL18494157 | 0.94 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL18489275 | 0.94 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL18493347 | 0.94 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL22762136 | 0.94 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL19300362 | 0.94 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2021-11-25 | — | — | US | disclosed |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200384085-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200231638-A1 | STABILIZED ANTI-MICROBIAL PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20200040048-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | AILERON THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10030049-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200384085-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | HRH4 1253/4885HRH3 1725/4885CYP19A1 3820/4885 |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | HRH4 1644/4885HRH3 2078/4885CYP19A1 3464/4885 |
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | HIF1A, HIF1AN, EGLN3 | HRH4 1456/4885HRH3 875/4885CYP19A1 797/4885 |
| US-10030049-B2 | Triazole macrocycle systems | FLT3, VIP, NGLY1 | HRH4 1806/4885HRH3 1158/4885CYP19A1 2366/4885 |
| US-20200040048-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | FLT3, BID, GRPR | HRH4 3042/4885HRH3 3034/4885CYP19A1 1854/4885 |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | BCL2L11, BCL2L1, BCL2L13 | HRH4 4318/4885HRH3 3975/4885CYP19A1 3501/4885 |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | FLT3, BID, GRPR | HRH4 3042/4885HRH3 3034/4885CYP19A1 1854/4885 |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | SCTR, GIPR, APLNR | HRH4 1644/4885HRH3 2078/4885CYP19A1 3464/4885 |
| US-20200231638-A1 | STABILIZED ANTI-MICROBIAL PEPTIDES | VIP, CTSA, HM13 | HRH4 1709/4885HRH3 1881/4885CYP19A1 4833/4885 |
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | HRH4 2639/4885HRH3 2900/4885CYP19A1 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.